The Balance Sheet as a WeaponNarrow moat

Intuitive Surgical (ISRG) — moat facet

$8.6 billion and no debt lets Intuitive remove the purchase decision entirely — which almost no competitor can match.

Intuitive can finance its own customers because it has more money than it can spend and nothing to repay.

The investment portfolio at end 2025 ($M)$3,368.0MCash and equivalents$2,566.9MShort-term investments$3,099.2MLong-term investments$2,517.0MTotal liabilities$9.03 billion of investments against $2,517.0M of total liabilities and no borrowing at all.
Enough money to remove the purchase decision entirely. It also earned $365.9M of interest — more than a tenth of pre-tax income, for doing nothing.

At 30 June 2026 it held $8.63 billion in cash, cash equivalents and investments1; at the end of 2025 the figure was $9.03 billion, split between $3,368.0 million of cash, $2,566.9 million of short-term investments and $3,099.2 million of long-term investments2. Total liabilities were $2,517.0 million against total assets of $20,458.7 million, and there is no borrowing in the capital structure at all.

That portfolio produced $365.9 million of interest and other income in 20253 — more than a tenth of pre-tax income, earned by doing nothing. It is also what makes the leasing strategy possible: a company placing 872 systems a year on its own balance sheet is running a finance operation, and Intuitive funds it from cash rather than from debt or securitisation.

The strategic value is competitive rather than financial. A challenger with a credible robot still has to persuade a hospital to buy it; Intuitive can simply remove the purchase. Very few of the named competitors could match that without straining a balance sheet, and the two that could — Johnson & Johnson and Medtronic4 — have shareholders who would ask what the return is.

The cost is a return on capital that looks worse than the business is. The standard calculation puts return on invested capital at 17.0% in 20255; strip out the whole investment portfolio, which does no operating work, and the return on what actually operates is nearer 29%6.

Set interest income against operating income: $365.9 million against $2,945.5 million. Rising sharply would mean the cash pile has outgrown the uses for it, which is a capital-allocation question rather than an operating one.

Moat trajectory: Widening

$8.6 billion of cash and investments with no debt, growing on operating cash flow no competitor in robotic surgery can match. The capacity to remove the purchase decision entirely is getting larger.

The number that tests this moat
Reported
Cash and investments against borrowings
$8.63 billion against none

Enough to finance its own customers indefinitely, which removes the purchase decision a challenger needs a hospital to make. Watch interest income against operating income — $365.9M against $2,945.5M — because a rising ratio means the cash has outgrown its uses.

Source: Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 ↗
⚠ Threats to the moat
⚠ THREAT 01
Nine Billion Dollars Doing Nothing Is a Question, Not an Asset
The portfolio is 44% of the balance sheet and the reason the reported return on capital looks mediocre.
References
  1. ReportedAt 30 June 2026 it held $8.63 billion in cash, cash equivalents and investments; at the end of 2025 the figure was $9.03 billion, split between $3,368.0 million of cash, $2,566.9 million of short-term investments and $3,099.2 million of...
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  2. ReportedAt 30 June 2026 it held $8.63 billion in cash, cash equivalents and investments; at the end of 2025 the figure was $9.03 billion, split between $3,368.0 million of cash, $2,566.9 million of short-term investments and $3,099.2 million of...
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  3. ReportedThat portfolio produced $365.9 million of interest and other income in 2025 — more than a tenth of pre-tax income, earned by doing nothing.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
  4. ReportedVery few of the named competitors could match that without straining a balance sheet, and the two that could — Johnson & Johnson and Medtronic — have shareholders who would ask what the return is.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
  5. Moat Explorer calcThe standard calculation puts return on invested capital at 17.0% in 2025; strip out the whole investment portfolio, which does no operating work, and the return on what actually operates is nearer 29%.
    Moat Explorer calculation from Intuitive's SEC XBRL filings (tools_roic_edgar.py): NOPAT divided by average operating invested capital, 17.0% in 2025 - and nearer 29% once the $9.03 billion investment portfolio, which does no operating work, is excluded from the denominator — 2015-2025 · publ. September 2026 · source ↗
  6. Moat Explorer calcThe standard calculation puts return on invested capital at 17.0% in 2025; strip out the whole investment portfolio, which does no operating work, and the return on what actually operates is nearer 29%.
    Moat Explorer calculation from Intuitive's SEC XBRL filings (tools_roic_edgar.py): NOPAT divided by average operating invested capital, 17.0% in 2025 - and nearer 29% once the $9.03 billion investment portfolio, which does no operating work, is excluded from the denominator — 2015-2025 · publ. September 2026 · source ↗
Sources
Generated September 23, 2026